News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
A new weapon in the global fight against malaria
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations
Subscribe To Our Newsletter & Stay Updated
